MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.18.01575

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.

Randall Marcus E, Filiaci Virginia, McMeekin D Scott, von Gruenigen Vivian, Huang Helen, Yashar Catheryn M, Mannel Robert S, Kim Jae-Weon, Salani Ritu, DiSilvestro Paul A, Burke James J, Rutherford Thomas, Spirtos Nick M, Terada Keith, Anderson Penny R, Brewster Wendy R, Small William, Aghajanian Carol A, Miller David S

Клиническое исследование III фазыСтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

PURPOSE: The primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate and high-risk early-stage endometrial carcinoma.

PATIENTS AND

METHODS

A randomized phase III trial was performed in eligible patients with endometrial cancer. Eligible patients had International Federation of Gynecology and Obstetrics (2009) stage I endometrioid histology with Gynecologic Oncology Group protocol 33-based high-intermediate-risk criteria, stage II disease, or stage I to II serous or clear cell tumors. Treatment was randomly assigned between RT (45 to 50.4 Gy over 5 weeks) or VCB followed by intravenous paclitaxel 175 mg/m2 (3 hours) plus carboplatin (area under the curve, 6) every 21 days for three cycles.

RESULTS

The median age of the 601 patients was 63 years, and 74% had stage I disease. Histologies included endometrioid (71%), serous (15%), and clear cell (5%). With a median follow-up of 53 months, the 60-month RFS was 0.76 (95% CI, 0.70 to 0.81) for RT and 0.76 (95% CI, 0.70 to 0.81) for VCB/C (hazard ratio, 0.92; 90% confidence limit, 0.69 to 1.23). The 60-month overall survival was 0.87 (95% CI, 0.83 to 0.91) for RT and 0.85 (95% CI, 0.81 to 0.90) for VCB/C (hazard ratio, 1.04; 90% confidence limit, 0.71 to 1.52). Vaginal and distant recurrence rates were similar between arms. Pelvic or para-aortic nodal recurrences were more common with VCB/C (9% v 4%). There was no heterogeneity of treatment effect with respect to RFS or overall survival among clinical or pathologic variables evaluated.

CONCLUSION

Superiority of VCB/C compared with pelvic RT was not demonstrated. Acute toxicity was greater with VCB/C; late toxicity was similar. Pelvic RT alone remains an effective, well-tolerated, and appropriate adjuvant treatment in high-risk early-stage endometrial carcinomas of all histologies.

Для цитирования: Randall Marcus E, Filiaci Virginia, McMeekin D Scott, von Gruenigen Vivian, Huang Helen, Yashar Catheryn M, Mannel Robert S, Kim Jae-Weon, Salani Ritu, DiSilvestro Paul A, Burke James J, Rutherford Thomas, Spirtos Nick M, Terada Keith, Anderson Penny R, Brewster Wendy R, Small William, Aghajanian Carol A, Miller David S. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019. DOI: 10.1200/jco.18.01575.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.